Is faster better? Critics of House bill question risks of speeding FDA approval of drugs, devices
Skip to main content
MDHC_Logotype_white
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • This Week's News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • People
    • Regional News
    • Digital Edition
    • Cigna's MDLive acquisition could foster virtual-first plan development, analysts say
      As COVID surged, vaccines came too late for at least 400 medical workers
      Why AstraZeneca and J&J's vaccines, in use elsewhere, are still on hold in America
      Lawmakers probe if Cuomo's policy fueled nursing home deaths
    • As COVID surged, vaccines came too late for at least 400 medical workers
      Why AstraZeneca and J&J's vaccines, in use elsewhere, are still on hold in America
      Lawmakers probe if Cuomo's policy fueled nursing home deaths
      0928p1_nysna Rally 2_Dave Sanders_i.jpg
      New York State Nurses Association report finds over 26,000 nurse understaffing complaints filed in 2019 and 2020
    • Dr. Imran Andrabi
      Q&A: ThedaCare CEO says lessons from COVID-19 will inform new approaches to population health management
      The Check Up: Dr. Imran Andrabi
      The Check Up: Dr. Imran Andrabi of ThedaCare
      Hospitals confront water shortages in winter storm aftermath
      beaumont-hospital-royal-oak_i_i_i.jpg
      Beaumont says nearly 2,000 second-shot vaccinations canceled due to vaccine shortage
    • High MLRs inspire insurers to focus on quality improvements
      Blue Cross and Blue Shield of Oklahoma, OU Health Physicians mired in contract dispute
      Beyond the Byline: Insurers are betting on virtual-first plans as COVID-19 shifts care pathways
      Beyond the Byline: Insurers are betting on virtual-first plans as COVID-19 shifts care pathways - Transcript
    • Why AstraZeneca and J&J's vaccines, in use elsewhere, are still on hold in America
      Lawmakers probe if Cuomo's policy fueled nursing home deaths
      Questions arise about public disclosure of wasted vaccines
      Becerra confirmation starting to look more likely
    • Genomics firms taking advantage of SPACs trend to go public faster
      COVID-19 could dent hospital revenue by at least $53 billion in 2021, AHA says
      deloitte GDP image chart graph going up
      Sponsored Content Provided By Deloitte
      Breaking the cost curve
      By the Numbers: Largest taxable not-for-profit bond issuances, 2021
    • Teladoc reports $383.3M in fourth-quarter revenue, up 145%
      man and woman looking at ipad wearing face masks stock image
      Sponsored Content Provided By Surescripts
      Improvements to benefits data can enhance ePrescribing and the patient experience
      Oscar Health's $1B IPO sets the stage for more health tech exits in 2021
      A map of the U.S. with images of the coronavirus.
      The digital divide becomes a new social determinant of health
    • Why AstraZeneca and J&J's vaccines, in use elsewhere, are still on hold in America
      COVID vaccine websites violate disability laws, create inequity for the blind
      Walgreens to sell Labcorp COVID-19 PCR home collection kits over-the-counter
      angela karpf headshot
      Sponsored Content Provided By B. Braun
      Making patient safety a policy priority
    • Michael Jordan, Novant team up to address health equity
      Former Ascension CEO, the first to lead the health system, passes away
      Biden's pick to head CMS would be first Black woman to hold post
      RAKESH SURI MD_i.jpg
      Cleveland Clinic creates president of international operations position
    • Midwest
    • Northeast
    • South
    • West
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
    • The Affordable Care Act after 10 years
    • Dr. John Fischer
      Patient-reported outcomes tool for hernia surgery helps physicians improve care
      New care model helps primary-care practices treat obesity
      doctor with patient
      COVID-19 treatment protocol developed in the field helps patients recover
      Rachel Wyatt
      Project to curb pressure injuries in hospitals shows promise
    • What's next for on-demand telehealth companies?
      A CalOptima PACE vaccination clinic.
      Will COVID-19 be the catalyst for creating a more sustainable healthcare system?
      A map of the U.S. with images of the coronavirus.
      The digital divide becomes a new social determinant of health
      Ascension’s St. Mary’s Hospital Surgery Center at Towne Centre and Allegheny Health Network’s Bethel Park surgery center
      Hospitals see opportunity, risk in ambulatory surgery centers
    • Dr. Daniel Hall
      UPMC pilots machine learning, telehealth to inform patient transfers
      A woman being recorded using her inhaler on a smartphone.
      Digital check-ins, connected inhalers help control asthma
      A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
      A woman with a wearable sensor talking to her provider.
      Wearable sensors help diagnose heart rhythm problems in West Virginia
  • Transformation
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • What's next for on-demand telehealth companies?
      Rising prescription copays drop adherence, spike mortality, research shows
      Dr. John Fischer
      Patient-reported outcomes tool for hernia surgery helps physicians improve care
      Highmark Health inks six-year cloud, tech deal with Google
    • Hospitals' Medicare billing practices suggest upcoding, OIG says
      California hospitals prepare ethical protocol to prioritize lifesaving care
      Amazon, JPMorgan Chase, Berkshire Hathaway disband Haven
      Digital pathways poised to reshape healthcare continuum in 2021
    • Dr. Daniel Hall
      UPMC pilots machine learning, telehealth to inform patient transfers
      A woman being recorded using her inhaler on a smartphone.
      Digital check-ins, connected inhalers help control asthma
      Humana partners with in-home provider for 24/7 care
      A phone screen showing the question, "Mary we hope this information was helpful and we'd like to keep guiding you. Are you interested in knowing when it's your turn to receive the vaccine?"
      Chatbots, texting campaigns help manage influx of COVID vax questions
    • Coordinated payment policies could speed transition to value, experts say
      CMMI's geographic direct contracting model needs an overhaul, experts say
      Hospitals fight UnitedHealthcare policies over lab test, specialty drug payments
      Cigna eliminates prior authorization for coronary CT scans
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
    • Health Systems Financials
      Executive Compensation
      Physician Compensation
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
    • Dr. Alan Kaplan
      The risks, rewards of taking organizations 'where they haven’t gone before'
      Wellstar CEO calls adapting for the pandemic her bold move
      Howard P. Kern
      Recognizing the value of telehealth in its infancy
      Dr. Stephen Markovich
      A bold move helped take him from family doctor to OhioHealth CEO
    • Dr. Stephen Markovich
      Making sure we're aligned along the path to achieving inclusion
      Barry Ostrowsky
      Ending racism is a journey taken together; the starting point must be now
      Laura Lee Hall and Gary Puckrein
      Increased flu vaccination has never been more important for communities of color
      John Daniels Jr.
      Health equity: Making the journey from buzzword to reality
    • In-person visitation must be part of the national COVID-19 response
      We've lost so much to the pandemic, but we've also made gains that will endure
      Medical groups key to meeting president's vaccine pledge
      We need a better social care referral loop, but it requires technology as well as the human touch
    • Letters: Eliminating bias in healthcare needs to be ‘deliberate and organic’
      Letters: Maybe dropping out of ACOs is a good thing for patients
      Letters: White House and Congress share blame for lack of national COVID strategy
      Letters: VA making strides to improve state veterans home inspections
    • Sponsored Content Provided By Optum
      How blockchain could ease frustration with the payment process
      Sponsored Content Provided By Optum
      Three steps to better data-sharing for payer and provider CIOs
      Sponsored Content Provided By Optum
      Reduce total cost of care: 6 reasons why providers and payers should tackle the challenge together
      Sponsored Content Provided By Optum
      Why CIOs went from back-office operators to mission-critical innovators
  • Awards
    • Award Programs
    • Nominate
    • Previous Award Programs
    • Other Award Programs
    • Best Places to Work in Healthcare Logo for Navigation
      Nominations Open - Best Places to Work in Healthcare
      Nominations Open - 50 Most Influential Clinical Executives
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Minorities in Healthcare
      • - Luminaries
      • - Top 25 Minority Leaders
      • - Minorities to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Excellence in Nursing Awards
    • Design Awards
    • Top 25 COOs in Healthcare
    • 100 Top Hospitals
    • ACHE Awards
  • Events
    • Conferences
    • Galas
    • Webinars
    • COVID-19 Event Tracker
    • podium march webinar logo lockup
      Sponsored Content Provided By Podium
      Webinar: Critical Touchpoints for Every Patient’s Journey — How Technology Plays an Important Role
      scp health logo lockup march 2021
      Sponsored Content Provided By SCP Health
      Webinar: COVID’s call to action — Reset for success in 2021
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Healthcare Transformation Summit
    • Leadership Symposium
    • Virtual Briefings
      • - Hospital of the Future
      • - Mental Health
      • - Patient Safety & Quality
      • - Strategic Marketing
      • - Virtual Health
      • - Workplace of the Future
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Minority Leaders Gala
    • Top 25 Women Leaders Gala
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
    • Next Up Podcast: Educating patients on the COVID-19 vaccine with Tanya Andreadis
      Dr. Joseph Cacchione
      Next Up Podcast: Educating patients on the COVID-19 vaccine with Dr. Joseph Cacchione
      Dr. Karen DeSalvo
      Next Up Podcast: What to expect with telehealth and healthcare technology in the next four years
      Carter Dredge
      Next Up Podcast: Ready, set, innovate! Innovation and disruption in healthcare
    • Beyond the Byline: Insurers are betting on virtual-first plans as COVID-19 shifts care pathways
      Beyond the Byline: How residents' stories shape our coverage of the vaccination rollout in nursing homes
      Beyond the Byline: Regulators aim to boost value push with fraud and abuse law updates
      An older man wearing a mask receiving a vaccine.
      Beyond the Byline: Verifying information on the chaotic COVID-19 vaccine rollout
    • Outreach during COVID-19
      Leading intention promote diversity and inclusion
      Introducing Healthcare Insider Podcast
    • The Check Up: Dr. Imran Andrabi
      The Check Up: Dr. Imran Andrabi of ThedaCare
      The Check Up: Tanya Blackmon
      The Check Up: Tanya Blackmon of Novant Health
      The Check Up: Dr. Patrick Hwu
      The Check Up: Dr. Patrick Hwu of the Moffitt Cancer Center
      The Check Up: Suresh Gunasekaran
      The Check Up: Suresh Gunasekaran of the University of Iowa Hospitals & Clinics
    • ivana naeymi-rad one on one intelligent medical objects
      Video: Ivana Naeymi Rad of Intelligent Medical Objects
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
April 08, 2015 01:00 AM

Is faster better? Critics of House bill question risks of speeding FDA approval of drugs, devices

Steven Ross Johnson
  • Tweet
  • Share
  • Share
  • Email
  • More
    Print
    Getty Images
    Dr. Margaret Hamburg criticized the 21st Century Cures Act in her final speech before stepping down as FDA commissioner.

    House Republicans are promoting a broad new bill supported by drugmakers and medical-device manufacturers that they say would make promising medications and devices available to the public faster and significantly reduce the costs associated with product development.

    But critics, including the recently departed commissioner of the Food and Drug Administration, say the 21st Century Cures Act could heighten the risk of patients being exposed to inadequately tested and potentially harmful products while increasing healthcare spending on high-cost drugs and products of marginal value. In addition, it would let manufacturers apply for longer market exclusivity, thus giving them more protection from generic competition and potentially boosting healthcare costs.

    Before stepping down as FDA commissioner last month, Dr. Margaret Hamburg called the legislative effort to speed up the drug development process “a terrible mistake” that could harm patients and drugmakers.

    In an interview with Modern Healthcare Wednesday, Hamburg challenged the idea that mandating shorter review times will make promising products available to patients more quickly. "Shortening review times is not going to create the scientific understanding and the research and development that needs to be done to translate exciting opportunities in science into new products," she said. “That is the wrong mechanism to achieve that goal.”

    Hamburg said she was enthusiastic about Congress' efforts to establish a strong national strategy for the advancement of biomedical product innovation. But she warned that any legislation should focus on what she called “real barriers to progress” and should not try to fix “perceived problems” that are not actually getting in the way.

    The Pharmaceutical Research and Manufacturers of America and the Advanced Medical Technology Association strongly support the bill. JC Scott, senior executive vice president of government affairs for AdvaMed, called it a major opportunity to address inefficiencies involved in the FDA review process. Some of the proposals in the bill, he said, would make review of medical devices more efficient and less cumbersome, reducing the cost to bring a product to market.

    A 2010 industry study estimated it cost companies an average of $24 million in FDA-related activities to bring a low- to moderate-risk medical device from concept to market, while it took around $75 million to take higher-risk devices through the agency's regulatory process.

    “We often talk about improving the regulatory review process, but it's not always about making it faster,” Scott said. “It's also about making it more efficient and predictable for companies to go through that process.”

    Debate over the bill comes as elected officials around the country are facing growing pressure from desperate patients and their families to make new medical products more quickly available on a compassionate-use basis. Nearly a dozen states have passed so-called “right to try” laws that allow terminally ill patients to seek an experimental drug without going through the FDA's compassionate-use process.

    The rationale for the laws—which are being pushed by the conservative advocacy group the Goldwater Institute—is that the FDA's program is too slow to make potentially lifesaving drugs accessible. Critics say such laws have no practical impact that would help patients get quicker access to unapproved therapies since manufacturers are not required to make their products available. Companies may fear that making products for compassionate use could undermine their clinical testing process and jeopardize FDA approval.

    In January, House Energy and Commerce Committee Chairman Fred Upton (R-Mich.) released a 393-page draft of the proposed legislation (PDF). The bill initially had bipartisan support, but House Democrats have turned against it citing concerns that it would weaken regulation of medical product development and potentially put the public at risk.

    “I am disappointed that the discussion document released … by Chairman Upton does not reflect true bipartisan collaboration,” said Rep. Frank Pallone Jr. of New Jersey, the ranking Democrat on the committee, in a written statement. He said the bill in its current form “could create more problems for our healthcare system than it solves.”

    Vijay Das, a healthcare advocate at the consumer advocacy organization Public Citizen, in Washington D.C., said many Democratic lawmakers see the bill in its current form as too “deregulatory,” catering to the interests of the drug and device industries.

    A key provision of the bill would change the FDA's current “breakthrough therapy designation,” a program that began as part of the 2012 FDA Safety and Innovation Act. That law allows the agency to identify drugs whose early clinical evidence shows they may be a significant improvement over current treatments for a serious or life-threatening disease or condition in order to help speed up their review.

    Under the 21st Century Cures Act, the FDA could grant market approval to a drug with breakthrough designation based on its early-stage testing for safety and effectiveness. After starting to market the drug, the drug's manufacturer would be required to conduct clinical trials to demonstrate safety and effectiveness. Medical-device makers also would be able to apply for breakthrough designation for products that treat conditions where no alternative exist, or that significantly improve on currently approved therapies.

    The bill also would require the FDA to create a new regulatory pathway for antibacterial medications that would allow for faster approval of such drugs by limiting their initial use to specific populations with severe conditions where current therapies have been ineffective. Other provisions of the bill would put new requirements on the FDA to shorten the length of time it traditionally takes to approve a new drug or medical device.

    Though experts say these provisions would help accelerate the review of new drugs, critics express concern that such measures would limit clinical testing of new therapies before they entered the market. That increases safety risks to the public.

    “The more you speed the process up at the beginning stages—Phase 1 and 2—the more I think you have to toughen up at Phase 4 when things are out in the world and you're trying to see what's going on,” said Arthur Caplan, a bioethicist at NYU Langone Medical Center. But, he said, “I don't think the FDA is talking about really making Phase 4 tougher.”

    Under the FDA's clinical trial process, products in Phase 4 testing already have been granted market approval but remain under FDA review for potential safety risks.

    Hamburg said placing additional requirements on the FDA in terms of its oversight responsibilities will increase the demands on an already overstretched FDA staff, hampering the review process. “Let's really focus on what's going to make a real meaningful, measurable difference in terms of what needs to be done and focus on those activities,” she said.

    Among the more popular measures of the bill is a requirement for the FDA to incorporate patient-reported outcome data within its review process to assess a drug's benefits and its tolerable risks. The bill also calls for additional funding for the National Institutes of Health, although it does not specify any level of funding. In addition, it would expedite the review process for vaccines.

    Gregory Daniel, managing director for evidence development and innovation at the Brookings Institution's Center for Health Policy, said he supports some parts of the bill but that it needs more detail, particularly on funding levels to make these reforms possible. “All of this together seems to be going in the right direction toward ensuring that patients have the opportunity to receive really important therapies that address unmet need as quickly as possible,” he said.

    Caplan said the bill offers some ways to speed up the regulatory process that “made sense.” One is the broader use of surrogate endpoints, which the agency already uses to predict the likely clinical outcome of a treatment earlier in its review process without spending the years or decades it could take to observe the actual patient outcomes.

    Though useful, Caplan warned surrogate endpoints cannot fully predict the long-term risks of a drug. “There's just no way that you can use substitute endpoints and not create more risk for people down the road,” he said. “It's just not as reliable. You get speed, and that's good. But you up the risk.”

    Other parts of the 21st Century Cures bill are more controversial. One is a provision intended to improve the FDA's “compassionate use” program that allows access to experimental medications to terminally ill patients on a case-by-case basis. Under the bill, drug companies seeking faster approval of an experimental therapy would be required to make their policies concerning access to those therapies for compassionate use public. That would include an explanation of their application process and notification to patients if their request has been denied and why. The provision appears to be a response to the growing number of “right to try” laws.

    Caplan noted, however, that the 21st Century Cures Act would not require a manufacturer to make an experimental therapy available for compassionate use. Rather, the company simply has to establish a compassionate-use policy. “It looks like it's tough in terms of saying you need a policy, but the policy could be that a company simply doesn't do it,” he said.

    The legislation also would offer incentives for drugmakers to develop innovative therapies by extending by several years the length of time their products would have market exclusivity. Manufacturers would be able to apply for up to 15 years of patent protection for a product if it was intended to treat “one or more unmet need.” Currently new biologic drugs can receive the maximum of 12 years of market exclusivity, with five years for new chemical drugs and seven years for orphan drugs.

    Allowing longer market exclusivity for such a broadly defined category of products raises the possibility that most new drugs would qualify. That could drive up drug spending. Caplan said granting longer market exclusivity would make it “tougher to maintain cost containment.”

    It could make consumers and payers wait longer before getting access to cheaper generic alternatives. Some experts say the extended market exclusivity period proposed under the bill could make it even more difficult for patients to afford high-cost drugs such as Gilead Sciences' hepatitis C drug, Sovaldi.

    But Daniel of the Brookings Institution said market exclusivity in areas of unmet need might offer needed investment incentives. And the bill's other proposed reforms would “facilitate smaller, faster, smarter clinical trials that get these potentially curative, higher-cost medications on the market quicker, and that will force a lot of new ways of thinking about value.” He said the healthcare system should be looking not at the sticker price of a drug but “at what value can that particular therapy bring to treating a patient.”

    Former FDA Commissioner Hamburg said financial incentives play an important role in drug development but the issue needs more analysis to determine what types of incentives are the most effective and do the most public good.

    "What we really need is to make sure that all of the components of the ecosystem are aligned so that we can build the science, have a streamlined efficient research and development plan, and move the opportunities in science as quickly as possible into products that will make a difference for patients and consumers while adhering to strong established standards for safety and efficacy,” she said.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Mistakes were made in regulation of coronavirus serology tests, FDA officials acknowledge
    Mistakes were made in regulation of coronavirus serology tests, FDA officials acknowledge
    States rush to catch up on delayed vaccines, expand access
    States rush to catch up on delayed vaccines, expand access
    Sponsored Content
    Get Free Newsletters

    Sign up for free enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today

    The weekly magazine, websites, research and databases provide a powerful and all-encompassing industry presence. We help you make informed business decisions and lead your organizations to success.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS
    • Instagram

    Stay Connected

    Join the conversation with Modern Healthcare through our social media pages

    MDHC_Logotype_white
    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2021. Crain Communications, Inc. All Rights Reserved.
    • News
      • This Week's News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Transformation
      • Patients
      • Operations
      • Care Delivery
      • Payment
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Award Programs
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top 25 Innovators
        • Minorities in Healthcare
          • - Luminaries
          • - Top 25 Minority Leaders
          • - Minorities to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Nominate
      • Previous Award Programs
        • Excellence in Nursing Awards
        • Design Awards
        • Top 25 COOs in Healthcare
      • Other Award Programs
        • 100 Top Hospitals
        • ACHE Awards
    • Events
      • Conferences
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Healthcare Transformation Summit
        • Leadership Symposium
        • Virtual Briefings
          • - Hospital of the Future
          • - Mental Health
          • - Patient Safety & Quality
          • - Strategic Marketing
          • - Virtual Health
          • - Workplace of the Future
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Minority Leaders Gala
        • Top 25 Women Leaders Gala
      • Webinars
      • COVID-19 Event Tracker
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing